FGFR gene fusions have been reported in the literature in approximately 8–10% of solid tumors and around 0.2% of NSCLC cases, with FGFR3::TACC3 being the most frequently identified variant. This evidence concerns the gene FGFR3 and non-small cell lung carcinoma.